Sigilon Therapeutics is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 62 staff and has a trailing 12-month revenue of around $17.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $22.47 |
|---|---|
| 52-week range | $20.61 - $23.79 |
| 50-day moving average | $17.35 |
| 200-day moving average | $10.36 |
| Wall St. target price | $21.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-14.83 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $22.47 from 2023-08-18
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-26) | 7.36% |
|---|---|
| 2 years (2022-07-26) | 2,856.58% |
| 3 years (2021-07-26) | 347.61% |
| 5 years (2019-07-22) | N/A |
| Revenue TTM | $17.7 million |
|---|---|
| Gross profit TTM | $-24,687,000 |
| Return on assets TTM | -23.65% |
| Return on equity TTM | -76.31% |
| Profit margin | -171.29% |
| Book value | $10.97 |
| Market Capitalization | $56.2 million |
TTM: trailing 12 months
We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.
Sigilon Therapeutics's shares were split on a 1:13 basis on 22 May 2023. So if you had owned 13 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sigilon Therapeutics shares – just the quantity. However, indirectly, the new 1200% higher share price could have impacted the market appetite for Sigilon Therapeutics shares which in turn could have impacted Sigilon Therapeutics's share price.
Over the last 12 months, Sigilon Therapeutics's shares have ranged in value from as little as $20.61 up to $23.785. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sigilon Therapeutics's is 4.115. This would suggest that Sigilon Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Sigilon Therapeutics's beta into context you can compare it against those of similar companies.
Sigilon Therapeutics, Inc. , a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.